Barclays
FBRX

Barclays’s Forte Biosciences FBRX Stock Holding History

Barclays’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.7K Sell
4,362
-8,906
-67% -$211K ﹤0.01% 4069
2026
Q1 		$344K Sell
13,268
-10,843
-45% -$312K ﹤0.01% 3397
2025
Q4 		$658K Buy
24,111
+23,291
+2,840% +$408K ﹤0.01% 3697
2025
Q3 		$12.3K Buy
+820
New +$9.45K ﹤0.01% 5005
2024
Q4 		– Sell
-1
Closed -$6 – 5337
2024
Q3 		$6 Buy
+1
New +$10 ﹤0.01% 5247
2022
Q3 		– Sell
-26
Closed -$1K – 4898
2022
Q2 		$1K Sell
26
-73
-74% -$2.32K ﹤0.01% 4934
2022
Q1 		$3K Buy
+99
New +$3.75K ﹤0.01% 4751
2020
Q2 		– Sell
-19
Closed -$9K – 5757
2020
Q1 		$9K Sell
19
-38
-67% -$14.8K ﹤0.01% 5840
2019
Q4 		$11K Buy
57
+27
+90% +$6.12K ﹤0.01% 6081
2019
Q3 		$7K Sell
30
-6
-17% -$9.11K ﹤0.01% 6414
2019
Q2 		$91K Buy
36
+17
+89% +$50.4K ﹤0.01% 5758
2019
Q1 		$75K Buy
+19
New +$73.4K ﹤0.01% 5580
2018
Q4 		– Sell
-18
Closed -$77.5K – 6793
2018
Q3 		$105K Buy
18
+14
+350% +$53.3K ﹤0.01% 5497
2018
Q2 		$13K Sell
4
-11
-73% -$40.3K ﹤0.01% 6403
2018
Q1 		$68K Buy
15
+7
+88% +$32.4K ﹤0.01% 5651
2017
Q4 		$29K Sell
8
-14
-64% -$55.9K ﹤0.01% 6091
2017
Q3 		$105K Buy
+22
New +$98K ﹤0.01% 4897
2017
Q2 		– Hold
0
– – – 6725

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Barclays's FBRX Position: Q2 2026 in Review

Barclays reduced its Forte Biosciences (FBRX) stake by 67% in Q2 2026, selling an estimated $211K and leaving 4,362 shares worth $92.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4069.

Barclays first reported a position in FBRX in Q3 2017 and has held it in 17 quarters since. The position peaked at $658K in Q4 2025. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Barclays held 4,362 shares of Forte Biosciences worth $92.7K as of Q2 2026.
  • Barclays sold 8,906 Forte Biosciences shares in Q2 2026, an estimated $211K.
  • Forte Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4069 holding.
  • Barclays first reported a position in Forte Biosciences in Q3 2017 and has held it in 17 quarters since.
  • Barclays's Forte Biosciences position peaked at $658K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.